Reports

Sale

Obsessive Compulsive Disorder Treatment Market

Global Obsessive Compulsive Disorder Treatment Market Share, Growth, Forecast: By Age Group: Adults, Paediatrics, Others; By Therapy Type: Cognitive Behavioural Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization, Others; By Severity; By Treatment Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Obsessive Compulsive Disorder Treatment Market Outlook

The global obsessive-compulsive disorders treatment market size attained a value of USD 508.62 million in 2023, driven by the increasing prevalence of the disorder and higher adoption of OCD medications in the high-income countries. The market is anticipated to grow at a CAGR of 9.1% during the forecast period of 2024-2032 to attain a value of USD 1,113.83 million by 2032.

 

obsessive compulsive disorder treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Obsessive Compulsive Disorder treatment Insights

Obsessive compulsive disorder treatment (OCD) is a chronic mental illness characterised by obsessions, compulsions, or both. Obsessions or persistent unwanted ideas that induce a strong want to repeat a certain behaviour are common in people with OCD. The person then acts out that impulse, or compulsion, in order to alleviate the obsessive thought.

 

Obsessions and compulsions are the two main categories of symptoms associated with OCD. Many people who have OCD have both obsessions and compulsions, but some only have one or the other.

 

These symptoms do not just pass through. Even lesser symptoms can consume at least an hour of your time each day and have a substantial impact on your daily activities.

 

Obsessions or compulsions may impair a person’s ability to concentrate on work or finish responsibilities. They may even prevent you from attending school, work, or anywhere else.

 

A few common obsessions in OCD include contamination obsessions, sexual obsessions, violent obsessions, religious/moral obsessions, perfectionism obsessions, responsibility obsessions, identity obsessions, among others.

 

Common compulsions in OCD include washing and cleaning, mental compulsions, checking, and repeating, among others.

 

The disorder has also been connected to abnormal brain development and impairment in particular parts of the brain. Some data suggest that OCD is related to how the brain responds to serotonin. Serotonin is a neurotransmitter that regulates mood and sleep, among many other functions in the body.

 

Risk Factors for OCD

Trauma or Stress: Significant stress at home, school, job, or in personal relationships can increase your risk of developing OCD or exacerbate existing symptoms. 

 

Childhood maltreatment: Children who have experienced abuse or other traumatic childhood experiences, such as bullying or severe neglect, are more likely to acquire the illness.

 

Acute Neuropsychiatric Symptoms in Childhood (CANS): Some children develop OCD as a result of an infection. This illness is recognised as PANDAS after a streptococcal infection. PANDAS stands for paediatric autoimmune neuropsychiatric disorders associated with streptococcus. Symptoms can be caused by different infections or disorders.

 

TBI (Traumatic Brain Injury): A head injury is one of the primary symptoms of the disorder.

 

Diagnosis for OCD

The following steps may be taken to assist in the diagnosis of obsessive compulsive disorder treatment :

 

Psychological Assessment: The doctor talks about the thoughts, feelings, symptoms, and behavioural patterns to see if the person has obsessive or compulsive habits that are interfering with the quality of life.

 

OCD Diagnostic Criteria: The doctor may use criteria from the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

 

Physical Examination: May be done to rule out any issues that could be causing your symptoms and to look for any complications.

 

According to the global congenital adrenal hyperplasia treatment market research report, the market can be categorised into the following segments: 

 

obsessive compulsive disorder treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Age Group

  • Adults
  • Pediatrics
  • Others

 

Market Breakup by Therapy Type

  • Cognitive Behavioural Therapy
  • Augmentation Therapy
  • Aversion Therapy
  • Systematic Desensitization
  • Others

 

Market Breakup by Severity

  • Mild
  • Moderate
  • Severe
  • Others

 

Market Breakup by Therapeutic Channel

  • Public
  • Private

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

obsessive compulsive disorder treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Obsessive Compulsive Disorder Treatment Epidemiology

OCD affects approximately 2.3% of the population or roughly one in every 40 adults and one in every 100 children in the United States. Females (1.8%) have a higher prevalence of OCD than males (0.5%). There is a 25% possibility that another direct family member will acquire symptoms in households with a history of OCD. 

 

The average age at which OCD symptoms start showing is 19.5 years. Males account for the vast majority of cases with relatively early onset. Almost a 5th of the male shows symptoms before the age of 10. Majority of girls are diagnosed with OCD throughout their youth (after age 10). People who develop OCD at a young age have more severe symptoms and greater incidences of ADHD and bipolar disorder.

 

Global Obsessive Compulsive Disorder Market Trends

One of the primary factors driving growth in the market for OCD drugs is the rising prevalence of the disorder. OCD is a severe mental condition that can endure for years. OCD is increasingly widespread in high-income countries due to a dramatic shift in people's lifestyles.

 

Throughout the forecast period, North America will account for the majority of market growth. In North America, drugs for obsessive compulsive disorder treatment are predominantly available in the United States and Canada. This region's market will grow faster than those in the rest of the world. The increased prevalence of OCD, government actions to combat OCD, and the availability of drugs would all contribute to the growth of the obsessive compulsive disorder pharmaceuticals market in North America over the forecast period.

 

Emerging Therapies

The US Food and Drug Administration approved the Ceruvia Lifesciences' Investigational New Drug (IND) Application for a Phase II clinical trial using synthetic psilocybin (SYNP-101) to treat obsessive compulsive disorder treatment (OCD) (FDA).

 

Numerous glutamatergic drugs are being studied. Medications that modulate the immune system and the inflammatory response are also being researched, and preliminary results are promising. Neurostimulation modalities are also being developed; preliminary evidence supports TMS, and the recent FDA clearance of TMS as an adjuvant for OCD will almost certainly lead to an increase in clinical use. 

 

Invasive surgical approaches, like as DBS and ablative operations, remain an option for treatment-refractory patients who have exhausted all other alternatives. Finally, in OCD, medicines with novel mechanisms of action and supplementary therapy methods are being researched.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global obsessive compulsive disorder market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows: 

 

  • Sun Pharmaceutical Industries Ltd.
  • H. Lundbeck A/S
  • Teva Pharmaceuticals USA, Inc.
  • Elli Lilly & Company
  • Apotex Inc.
  • Viatris Inc.
  • Lannett
  • GlaxoSmithKline Plc
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Age Group
  • Therapy Type
  • Severity
  • Treatment Channel
  • Region
Breakup by Age Group
  • Adults
  • Paediatrics
  • Others
Breakup by Therapy Type
  • Cognitive Behavioural Therapy
  • Augmentation Therapy
  • Aversion Therapy
  • Systematic Desensitization
  • Others
Breakup by Severity
  • Mild
  • Moderate
  • Severe
  • Others
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Sun Pharmaceutical Industries Ltd.
  • H. Lundbeck A/S
  • Teva Pharmaceuticals USA, Inc.
  • Elli Lilly & Company
  • Apotex Inc.
  • Viatris Inc.
  • Lannett
  • GlaxoSmithKline Plc
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
2    Research Methodology
3    Executive Summary
4    Obsessive-Compulsive Disorder Overview 

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Model
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate 
6    Current Scenario Evaluation 
    6.1    Emerging Therapies and Clinical Trials Synopsis
    6.2    Patent Landscape 
        6.2.1    Patent Overview
            6.2.1.1     Patent Status and Expiry
            6.2.1.2     Timelines from Drug Development to Commercial Launch
            6.2.1.3     New Drug Application
                6.2.1.3.1     Documentation and Approval Process
    6.3    Cost of Treatment
    6.4    Regulatory Framework
        6.4.1    Regulatory Overview
            6.4.1.1     US FDA
            6.4.1.2     EU EMA
            6.4.1.3     INDIA CDSCO
            6.4.1.4     JAPAN PMDA
            6.4.1.5     Others
7    Challenges and Unmet Needs
    7.1    Treatment Pathway Challenges
    7.2    Compliance and Drop-out Analysis
    7.3    Awareness and Prevention Gaps
8    Global Obsessive-Compulsive Disorder Treatment Market
    8.1    Global Obsessive-Compulsive Disorder Treatment Market Overview
    8.2    Global Obsessive-Compulsive Disorder Treatment Market Analysis 
        8.2.1    Market Overview
            8.2.1.1     Global Historical Obsessive-Compulsive Disorder Treatment Market Value (2017-2023) 
            8.2.1.2     Global Forecast Obsessive-Compulsive Disorder Treatment Market Value (2024-2032)
    8.3    Global Obsessive-Compulsive Disorder Treatment Market by Age Group
        8.3.1    Market Overview
            8.3.1.1.1     Adults
            8.3.1.1.2     Paediatrics
            8.3.1.1.3     Others
    8.4    Global Obsessive-Compulsive Disorder Treatment Market by Therapy Type
        8.4.1    Market Overview
            8.4.1.1.1     Cognitive Behavioural Therapy
            8.4.1.1.2     Augmentation Therapy
            8.4.1.1.3     Aversion Therapy
            8.4.1.1.4     Systematic Desensitization
            8.4.1.1.5     Others
    8.5    Global Obsessive-Compulsive Disorder Treatment Market by Severity 
        8.5.1    Market Overview
            8.5.1.1.1     Mild
            8.5.1.1.2     Moderate
            8.5.1.1.3     Severe
            8.5.1.1.4     Others
    8.6    Global Obsessive-Compulsive Disorder Treatment Market by Treatment Channel
        8.6.1    Market Overview
            8.6.1.1.1     Public
            8.6.1.1.2     Private
    8.7    Global Obsessive-Compulsive Disorder Treatment Market by Region
        8.7.1    Market Overview 
            8.7.1.1     North America 
            8.7.1.2     Europe 
            8.7.1.3     Asia Pacific 
            8.7.1.4     Middle East and Africa 
            8.7.1.5     Latin America 
9    North America Obsessive-Compulsive Disorder Treatment Market 
    9.1    Market Share by Country
    9.2    United States of America
        9.2.1    Historical Trend (2017-2023)
        9.2.2    Forecast Trend (2024-2032)
    9.3    Canada
        9.3.1    Historical Trend (2017-2023)
        9.3.2    Forecast Trend (2024-2032)
10    Europe Obsessive-Compulsive Disorder Treatment Market
    10.1    Market Share by Country
    10.2    United Kingdom
        10.2.1    Historical Trend (2017-2023)
        10.2.2    Forecast Trend (2024-2032)
    10.3    Germany
        10.3.1    Historical Trend (2017-2023)
        10.3.2    Forecast Trend (2024-2032)
    10.4    France
        10.4.1    Historical Trend (2017-2023)
        10.4.2    Forecast Trend (2024-2032)
    10.5    Italy
        10.5.1    Historical Trend (2017-2023)
        10.5.2    Forecast Trend (2024-2032)
    10.6    Others
11    Asia Pacific Obsessive-Compulsive Disorder Treatment Market
    11.1    Market Share by Country
    11.2    China
        11.2.1    Historical Trend (2017-2023)
        11.2.2    Forecast Trend (2024-2032)
    11.3    Japan
        11.3.1    Historical Trend (2017-2023)
        11.3.2    Forecast Trend (2024-2032)
    11.4    India
        11.4.1    Historical Trend (2017-2023)
        11.4.2    Forecast Trend (2024-2032)
    11.5    ASEAN
        11.5.1    Historical Trend (2017-2023)
        11.5.2    Forecast Trend (2024-2032)
    11.6    Australia
        11.6.1    Historical Trend (2017-2023)
        11.6.2    Forecast Trend (2024-2032)
    11.7    Others
12    Latin America Obsessive-Compulsive Disorder Treatment Market
    12.1    Market Share by Country
    12.2    Brazil
        12.2.1    Historical Trend (2017-2023)
        12.2.2    Forecast Trend (2024-2032)
    12.3    Argentina
        12.3.1    Historical Trend (2017-2023)
        12.3.2    Forecast Trend (2024-2032)
    12.4    Mexico
        12.4.1    Historical Trend (2017-2023)
        12.4.2    Forecast Trend (2024-2032)
    12.5    Others
13    Middle East and Africa Obsessive-Compulsive Disorder Treatment Market
    13.1    Market Share by Country
    13.2    Saudi Arabia
        13.2.1    Historical Trend (2017-2023)
        13.2.2    Forecast Trend (2024-2032)
    13.3    United Arab Emirates
        13.3.1    Historical Trend (2017-2023)
        13.3.2    Forecast Trend (2024-2032)
    13.4    Nigeria
        13.4.1    Historical Trend (2017-2023)
        13.4.2    Forecast Trend (2024-2032)
    13.5    South Africa
        13.5.1    Historical Trend (2017-2023)
        13.5.2    Forecast Trend (2024-2032)
    13.6    Others
14    Global Obsessive-Compulsive Disorder Treatment Market Dynamics
    14.1     Market Drivers and Constraints
    14.2     SWOT Analysis
    14.3     Porter’s Five Forces Model
    14.4     Key Demand Indicators
    14.5     Key Price Indicators
    14.6     Industry Events, Initiatives, and Trends 
    14.7     Value Chain Analysis
15    Supplier Landscape
    15.1    Sun Pharmaceutical Industries Ltd.
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2     H. Lundbeck A/S
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications
    15.3    Teva Pharmaceuticals USA, Inc.
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    Elli Lilly & Company
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5     Apotex Inc.
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6     Viatris Inc.
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7     Lannett
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8     GlaxoSmithKline Plc
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
    15.9    F. Hoffmann-La Roche Ltd
        15.9.1    Company Overview
        15.9.2    Product Portfolio
        15.9.3    Demographic Reach and Achievements
        15.9.4    Mergers and Acquisitions
        15.9.5    Certifications
    15.10    Pfizer Inc.
        15.10.1    Company Overview
        15.10.2    Product Portfolio
        15.10.3    Demographic Reach and Achievements
        15.10.4    Mergers and Acquisitions
        15.10.5    Certifications
16    Global Obsessive-Compulsive Disorder Treatment Market Distribution Model (Additional Insight)
    16.1    Overview 
    16.2    Potential Distributors 
    16.3    Key Parameters for Distribution Partner Assessment 
17    Payment Methods (Additional Insight)
    17.1    Government Funded
    17.2    Private Insurance
    17.3    Out-of-Pocket

Key Questions Answered in the Report

In 2023, the global market Obsessive Compulsive Disorder Treatment attained a value of USD 508.62 million.

The market is anticipated to grow at a CAGR of 9.1% during the forecast period of 2024-2032 to reach a value of USD 1,113.83 million by 2032.

The market growth is driven by the increasing prevalence of the disorder and higher adoption of OCD medications in the high-income countries.

Based on the age group, the market is categorised into adults and paediatrics, among others.

Based on the treatment, the market is segmented into cognitive behavioural therapy, augmentation therapy, aversion therapy, and systematic desensitization, among others.

The treatment channels in this market are public and private.

The different regions in the acute coronary syndrome treatment market are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.

The key companies involved in this market are Sun Pharmaceutical Industries Ltd., H. Lundbeck A/S, Teva Pharmaceuticals USA, Inc., Elli Lilly & Company, Apotex Inc., Viatris Inc., Lannett, GlaxoSmithKline Plc, F. and Hoffmann-La Roche Ltd, and Pfizer Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER